~~<i id='2F7F10C530'><strike id='2F7F10C530'><tt id='2F7F10C530'><pre id='2F7F10C530'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：hotspot 2025-09-30 16:23:31 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Why Charlie Gard's case is so disturbing to Americans

Wikipedia

focus

Wikipedia

entertainment

hotspot

Wikipedia

RONNYHARTMANN/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog

WSS

A virus, fished out of a lake, may have saved a man’s life

A virus, fished out of a lake, may have saved a man’s life

A Q&A with the global head of Boehringer Ingelheim's innovation unit

FDA panel signals lack of confidence in Amgen cancer drug data

A virus, fished out of a lake, may have saved a man’s life

Why Charlie Gard's case is so disturbing to Americans

entertainment

explore

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Researchers tackle phage therapy hurdles for wider adoption

Continuity nursing helped my family in our darkest PICU moments

Flagship Pioneering startup Sonata Therapeutics lays off 21

Sports medicine is finally prioritizing gender equality

Weight loss drugs aren’t covered by Obamacare. That may change

At least 13 dead in Texas as scorching temps continue

Abridge raises $150m as clinical notes automation market heats up

ChatGPT in medicine: STAT answers readers' burning questions

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

Flagship Pioneering startup Sonata Therapeutics lays off 21

New study raises questions about niacin and heart health

FDA warns medical device makers about rise in fabricated data

3 questions for the future of Biden's cancer moonshot

Was Amgen transparent enough on FDA's concern on cancer drug?

Measles policy set amid Florida outbreak alarms vaccine proponents

Wikipedia

entertainment

hotspot

Wikipedia